The concentration of bismuth will, of course, depend on the rate of absorption and excretion. Sollmann, Cole, and Henderson (1933) found that the percentage urinary excretion (the main route) was nearly uniform for all bismuth compounds-15 to 25 per cent. within 3 weeks. Sollmann (1948) later noted that about half of the retained bismuth was excreted in the first 3 weeks after administration was stopped, while the remainder was tenaciously retained.
The distribution of bismuth in the internal organs is of interest. According to Leonard (1928) Nephritis occurs among the clinical systemic toxic manifestations of bismuth therapy listed by Goodman and Gilman (1941). They commented that the accumulation of the element at the site of excretion favoured renal damage:
Nevertheless, as used clinically it rarely causes impairment of renal function or urinary evidence of parenchymatous damage. Kolmer, Brown, and Rule (1939) pointed out that the kidney lesion was essentially nephrotic, and that the nephrotoxic effect was related not only to elemental bismuth, but to the rate of its dissociation, absorption, and excretion. Although deaths from renal toxic effects following therapy (for syphilis and other conditions) with various bismuth compounds have been described, no cases so far have appeared incriminating sodium bismuth tartrate in ordinary doses as the cause of fatal renal tubular lesions. Dowds (1936) reported three delayed deaths following subcutaneous sodium bismuth administration in gross over-doses (approximately 25, -13, and 25 gr.); two of these cases showed marked renal symptoms and autopsy revealed kidney damage.
The bismuth preparation used in the case here reported contained 1 gr. sodium bismuthyl tartrate B.P. in 1 ml. isotonic dextrose solution. Approximately 1 gr. of elemental bismuth was administered. Within 11 weeks of the initiation of therapy the patient developed oedema, heavy albuminuria, and cylindruria. Subsequently the full typical nephrotic syndrome became manifest, and, despite temporary improvement, nitrogen retention developed and uraemic features preceded death. Although sodium bismuth tartrate is generally safe, it has been established, as indicated above, that all bismuth compounds may be cumulative and toxic, the toxicity depending on the bismuth content. Equally clear is the liability of sodium bismuth tartrate and other compounds to produce renal damage. Despite the small total intramuscular dosage the drug would appear to be responsible for the renal damage in this case. Summary (1) A case of nephrotic syndrome is described in a 39-year-old female following the injection of 2*5 gr. sodium bismuth tartrate for rheumatoid arthritis.
(2) It is noted that bismuth compounds, probably acting in a form common to all, manifest their therapeutic activity and toxicity in proportion to their elemental bismuth content.
(3) The danger of cumulative effect is indicated. (2) On note que les composes de bismuth, doues tous probablement d'une action similaire, manifestent leur activite therapeutique et leur toxicite en fonction de leur teneur en bismuth pur.
(3) On indique le danger de l'effet cumulatif. (4) On souligne, parmi les effets-toxiques, la lesion r6nale qui peut etre mortelle, comme le montre le cas d6crit.
Sindrome nefrotico despues del tratamiento de la artritis reumatoide con el tartrato sbdico de bismuto
SUMARIO
(1) Se describe un caso de sindrome nefr6tico en una mujer de 39 anios ocurriendo despues de una inyecci6n de 2,5 gr. de tartrato s6dico de bismuto al tratar su artritis reumatoide.
(2) Se nota que los compuestos de bismuto, todos probablemente dotados de una acci6n similar, manifestan su actividad terapeutica y su toxicidad en funci6n de su tenor de bismuto puro.
(3) Se indica el peligro del efecto cumulativo. (4) Se hace resaltar, entre los efectos t6xicos, la lesi6n renal que puede ser mortal, como en el caso descrito aqui.
